Capvizr

Praser Therapeutics Raises $50 billion Pre-Seed

Company profile · Healthcare & Life Sciences · Updated July 16, 2026

Praser Therapeutics has a tracked Pre-Seed round of $50 billion in Capvizr's funding dataset.

Pre-Seed$50 billionTotal tracked $50 billionUndisclosed HQ

What it does

Capvizr has a factual funding record for this company, but source material is too thin for MD-grade operating analysis.

Traction

No Limit Holdings participated in the latest tracked round; deeper traction analysis is held until source support is strong enough.

Trend impact

MD-grade thesis held: available source material is not specific enough to support a non-generic investor-economist read without overclaiming.

Funding history

  • July 16, 2026 · Pre-Seed · $50 billion · No Limit Holdings
Open Praser Therapeutics in the interactive Capvizr dashboard →